SCHEDULE: FMR LLC Discloses 10.3% Stake in Xenon Pharmaceuticals

FMR LLC and Abigail P. Johnson have reported a combined beneficial ownership of 10.3% in Xenon Pharmaceuticals Inc. common stock as of July 31, 2026.

Summary

• FMR LLC and Abigail P. Johnson, through various entities, collectively beneficially own 9,959,795.17 shares of Xenon Pharmaceuticals Inc. common stock.
• This holding represents 10.3% of the class of securities.
• The filing is an amendment (Amendment No. 8) to a Schedule 13G, indicating a change in reporting status or holdings.
• The reporting persons are classified as investment advisers (IA) and banks (BK) through their affiliated entities.
• The date of the event requiring this filing is July 31, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, primarily indicating a significant institutional holding without new strategic information.

Positives

• Significant institutional ownership by FMR LLC and Abigail P. Johnson, indicating confidence in Xenon Pharmaceuticals.
• The filing confirms a substantial holding, which can provide stability to the stock.

Negatives

• The filing does not provide new strategic information or financial performance data, making it difficult to assess the company's current operational health.
• The nature of a Schedule 13G filing is primarily informational regarding ownership, not a deep dive into company performance.

Risks

• Potential for future changes in FMR LLC's stake, which could impact share price.
• The filing does not detail specific reasons for the ownership level, leaving room for speculation.

Future Outlook

This filing is a Schedule 13G, which primarily reports on beneficial ownership and does not contain forward-looking statements or company guidance.

Management Comments

• FMR LLC and Abigail P. Johnson, through their affiliated entities, collectively beneficially own 9,959,795.17 shares, representing 10.3% of the outstanding common stock.
• The filing is made pursuant to Rule 13d-1(b) and indicates that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control.

Industry Context

StockSavvy.ai notes that significant institutional holdings, as reported in this Schedule 13G, are common in the biotechnology and pharmaceutical sectors, reflecting investor interest in companies with potential drug development pipelines. The 10.3% stake by FMR LLC is substantial and positions them as a key stakeholder.

Comparison to Industry Standards

• Institutional ownership in the biotechnology sector often ranges from 50% to 80% of outstanding shares.
• A 10.3% stake by a single entity like FMR LLC is considered a significant minority holding, often held by large asset managers or investment firms.
• Companies like Fidelity (affiliated with FMR LLC) are known to take substantial positions in promising companies within the healthcare and technology sectors.

Stakeholder Impact

• Shareholders: The significant stake held by FMR LLC may be viewed positively, suggesting institutional confidence, but also raises questions about potential future trading activity.
• Management: The substantial ownership by FMR LLC could influence board composition or strategic decisions if their stake were to increase or if they chose to engage more actively.
• Creditors: No direct impact is indicated by this filing.

Next Steps

• Monitor future filings from FMR LLC and Abigail P. Johnson for any changes in their beneficial ownership.
• Observe Xenon Pharmaceuticals Inc.'s strategic developments and financial performance, which may influence FMR LLC's holding decisions.

Key Dates

Keywords

Xenon Pharmaceuticals, FMR LLC, Abigail P. Johnson, Schedule 13G, Institutional Ownership, Common Stock, Investment Adviser, Beneficial Ownership